Should I buy or sell GeneDx stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GeneDx in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WGS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WGS, but not buy additional shares or sell existing shares. View WGS analyst ratings or view top-rated stocks .

What is GeneDx's stock price target for 2024?

1 brokerages have issued 12 month price objectives for GeneDx's stock. Their WGS share price targets range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price. View analysts price targets for WGS or view top-rated stocks among Wall Street analysts .

How have WGS shares performed in 2024?

GeneDx's stock was trading at $2.75 at the beginning of 2024. Since then, WGS stock has increased by 248.0% and is now trading at $9.57. View the best growth stocks for 2024 here .

When is GeneDx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 29th 2024. View our WGS earnings forecast .

How can I listen to GeneDx's earnings call?

GeneDx will be holding an earnings conference call on Monday, April 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were GeneDx's earnings last quarter?

GeneDx Holdings Corp. (NASDAQ:WGS) announced its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.01. The company had revenue of $57.42 million for the quarter, compared to analysts' expectations of $57 million. GeneDx had a negative net margin of 86.77% and a negative trailing twelve-month return on equity of 49.64%.

When did GeneDx's stock split?

GeneDx's stock reverse split on Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What guidance has GeneDx issued on next quarter's earnings?

GeneDx issued an update on its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $220.0 million-$230.0 million, compared to the consensus revenue estimate of $227.3 million.

How do I buy shares of GeneDx?

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:WGS

GeneDx (WGS) Stock Price, News & Analysis

→ Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad)

Free WGS Stock Alerts

$9.57

+0.37 (+4.02%)

(As of 04/18/2024 ET)

Compare

Today's Range: $8.63
▼
$9.62
50-Day Range: $3.90
▼
$12.01
52-Week Range: $1.16
▼
$12.24

Volume: 156,303 shs
Average Volume: 144,233 shs
Market Capitalization: $249.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get GeneDx alerts:

GeneDx MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 14.9% Upside
$11.00 Price Target
Short Interest: Bearish
6.78% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.57
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$349,600 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.02) to ($0.99) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.22 out of 5 stars

Medical Sector

755th out of 918 stocks

Health Services Industry

7th out of 10 stocks

2.0

Analyst's Opinion

Consensus Rating
GeneDx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
GeneDx has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.78% of the float of GeneDx has been sold short.
Short Interest Ratio / Days to Cover
GeneDx has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in GeneDx has recently increased by 4.76%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
GeneDx does not currently pay a dividend.
Dividend Growth
GeneDx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for WGS.

2.5

News and Social Media Coverage

News Sentiment
GeneDx has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for GeneDx this week, compared to 1 article on an average week.
MarketBeat Follows
4 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GeneDx insiders have bought 137.86% more of their company's stock than they have sold. Specifically, they have bought $349,600.00 in company stock and sold $146,979.00 in company stock.
Percentage Held by Insiders
28.10% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for GeneDx are expected to grow in the coming year, from ($2.02) to ($0.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GeneDx is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GeneDx is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GeneDx has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad The Bull Report

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic

About GeneDx Stock (NASDAQ:WGS)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

WGS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

WGS Stock News Headlines

March 20, 2024 | insidertrades.com

GeneDx Holdings Corp. (NASDAQ:WGS) Insider Kareem Saad Sells 2,008 Shares

April 16, 2024 | americanbankingnews.com

GeneDx (NASDAQ:WGS) Given New $11.00 Price Target at The Goldman Sachs Group

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

April 10, 2024 | americanbankingnews.com

GeneDx (NASDAQ:WGS) Trading 3.8% Higher

April 4, 2024 | globenewswire.com

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024

March 16, 2024 | finance.yahoo.com

WGS Apr 2024 7.500 call

March 16, 2024 | finance.yahoo.com

WGS Apr 2024 7.500 put

March 14, 2024 | globenewswire.com

GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

March 13, 2024 | edition.cnn.com

GeneDx Holdings Corp. Class A

February 26, 2024 | globenewswire.com

GeneDx to Participate in 44th Annual Cowen Health Care Conference

February 25, 2024 | finance.yahoo.com

WGS Mar 2024 7.500 put

February 23, 2024 | finance.yahoo.com

WGS Mar 2024 10.000 put

February 23, 2024 | benzinga.com

GeneDx Hldgs Stock (NASDAQ:WGS) Insider Trades

February 21, 2024 | finanznachrichten.de

GeneDx Holdings Corp.: GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

February 21, 2024 | benzinga.com

GeneDx Hldgs Stock (NASDAQ:WGS), Guidance and Forecast

February 21, 2024 | finance.yahoo.com

GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2023 Earnings Call Transcript

February 21, 2024 | markets.businessinsider.com

Here's what Wall Street expects from GeneDx's earnings

February 20, 2024 | markets.businessinsider.com

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

February 20, 2024 | finance.yahoo.com

GeneDx Holdings Corp (WGS) Reports Strong Revenue Growth and Margin Expansion in Q4 2023

February 20, 2024 | globenewswire.com

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

February 1, 2024 | finance.yahoo.com

GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024

January 31, 2024 | finance.yahoo.com

Institutional investors own a significant stake of 44% in GeneDx Holdings Corp. (NASDAQ:WGS)

January 24, 2024 | markets.businessinsider.com

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 8, 2024 | finanznachrichten.de

GeneDx Holdings Corp.: GeneDx Announces Preliminary 2023 Financial Results

January 8, 2024 | finance.yahoo.com

GeneDx Announces Preliminary 2023 Financial Results

December 18, 2023 | finance.yahoo.com

GeneDx Holdings Corp. (NASDAQ:WGS) Surges 52% Yet Its Low P/S Is No Reason For Excitement

See More Headlines

Receive WGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/29/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Health services
Sub-Industry: N/A
Current Symbol: NASDAQ:WGS
CUSIP: N/A
CIK: 1818331
Web: sema4.com
Phone: 800-298-6470
Fax: N/A
Employees: 1,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +14.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.44)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-175,770,000.00
Net Margins: -86.77%
Pretax Margin: -87.23%
Return on Equity: -49.64%
Return on Assets: -29.57%

Debt

Debt-to-Equity Ratio: 0.23
Current Ratio: 3.10
Quick Ratio: 2.95

Sales & Book Value

Annual Sales: $202.57 million
Price / Sales: 1.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.78 per share
Price / Book: 1.09

Miscellaneous

Outstanding Shares: 26,050,000
Free Float: 18,733,000
Market Cap: $249.30 million
Optionable: Optionable
Beta: 2.75

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Ms. Katherine A. Stueland (Age 48)
President, CEO & Director
Comp: $1.19M
Mr. Kevin Feeley
Chief Financial Officer
Ms. Karen Ponchner
Senior VP & Head of Operations
Mr. Eric Olivares Ph.D.
Chief Product & Technology Officer
Mr. Devin K. Schaffer J.D.
M.B.A., General Counsel
Mr. Paul Kruszka M.D.
Chief Medical Officer
Ms. Melanie Duquette
Chief Growth Officer
Sabrina Dunbar
Chief of Staff

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

WGS Stock Analysis - Frequently Asked Questions

Should I buy or sell GeneDx stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GeneDx in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WGS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WGS, but not buy additional shares or sell existing shares.
View WGS analyst ratings or view top-rated stocks.
What is GeneDx's stock price target for 2024?: 1 brokerages have issued 12 month price objectives for GeneDx's stock. Their WGS share price targets range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for WGS or view top-rated stocks among Wall Street analysts.
How have WGS shares performed in 2024?: GeneDx's stock was trading at $2.75 at the beginning of 2024. Since then, WGS stock has increased by 248.0% and is now trading at $9.57.
View the best growth stocks for 2024 here.
When is GeneDx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, April 29th 2024.
View our WGS earnings forecast.
How can I listen to GeneDx's earnings call?: GeneDx will be holding an earnings conference call on Monday, April 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were GeneDx's earnings last quarter?: GeneDx Holdings Corp. (NASDAQ:WGS) announced its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.01. The company had revenue of $57.42 million for the quarter, compared to analysts' expectations of $57 million. GeneDx had a negative net margin of 86.77% and a negative trailing twelve-month return on equity of 49.64%.
When did GeneDx's stock split?: GeneDx's stock reverse split on Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What guidance has GeneDx issued on next quarter's earnings?: GeneDx issued an update on its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $220.0 million-$230.0 million, compared to the consensus revenue estimate of $227.3 million.
How do I buy shares of GeneDx?: Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:WGS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GeneDx (WGS) Stock Price, News & Analysis

GeneDx MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About GeneDx Stock (NASDAQ:WGS)

WGS Stock Price History

WGS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

WGS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™